传染科

订阅

MedSci主页 / 所有栏目 / 传染科

防御南非变种！Moderna的变异特异性COVID-19候选疫苗即将进入临床阶段

2021-02-25 Allan MedSci原创

ModernaCovid-19moderna疫苗南非变种mRNA-1273.351
关注

Moderna近日表示，已经生产了COVID-19疫苗的更新版本，该疫苗旨在更好地防御南非SARS-CoV-2的B.1.351变种。

Moderna近日表示，已经生产了COVID-19疫苗的更新版本，该疫苗旨在更好地防御南非SARS-CoV-2的B.1.351变种。被称为mRNA-1273.351的候选疫苗已被运送到美国国家过敏和传染病研究所，将进行I期临床试验。

Moderna表示，它还计划评估另外两种增强免疫力的方法，以增强抵抗SARS-CoV-2突变的免疫力。包括被称为mRNA-1273.211的多价加强免疫候选物，它将在50 mcg或更低剂量中联合mRNA-1273或mRNA-1273.351。

除了这种加强策略外，该公司还表示计划在血清阴性个体中使用mRNA-1273.351和mRNA-1273.211作为针对COVID-19的主要疫苗，将以100 mcg或更低的剂量施用两种剂量的方案。

此外，Moderna表示，它将评估mRNA-1273.351和mRNA-1273.211在未接种疫苗的个体和以前接受过mRNA-1273的个体中的免疫原性和安全性。

 

原始出处：

https://www.firstwordpharma.com/node/1803892?tsid=4

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (14)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1937313, encodeId=036e193e313e5, content=<a href='/topic/show?id=d6262e4688b' target=_blank style='color:#2F92EE;'>#候选疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27468, encryptionId=d6262e4688b, topicName=候选疫苗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e5742500212, createdName=12498f17m66暂无昵称, createdTime=Mon Jan 03 08:44:46 CST 2022, time=2022-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2008782, encodeId=81742008e82e2, content=<a href='/topic/show?id=db6969548d' target=_blank style='color:#2F92EE;'>#eRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6954, encryptionId=db6969548d, topicName=eRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Mon Jan 10 03:44:46 CST 2022, time=2022-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2025281, encodeId=611b20252812b, content=<a href='/topic/show?id=6b8a230e815' target=_blank style='color:#2F92EE;'>#临床阶段#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23078, encryptionId=6b8a230e815, topicName=临床阶段)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d39f177, createdName=lixiao3326, createdTime=Fri Jan 14 04:44:46 CST 2022, time=2022-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=952867, encodeId=462995286e9b, content=赚积分, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=82d12201325, createdName=黑布林, createdTime=Wed Mar 31 18:41:37 CST 2021, time=2021-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899462, encodeId=345b1899462b3, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Wed Aug 04 23:44:46 CST 2021, time=2021-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=947905, encodeId=ec0294e9053a, content=！, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqicXS4Klkk29P7uiaLsaE4sM2BIzwEbpMXmDq9icj7Pia2Piaf90l5zdma3uAsLBz3YOLXiaSPNh5VJWpw/132, createdBy=e1aa2416324, createdName=真真日上, createdTime=Sat Mar 13 17:55:21 CST 2021, time=2021-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=944616, encodeId=36e594461645, content=期待结果, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e83131645, createdName=caicunliang, createdTime=Tue Mar 02 00:07:51 CST 2021, time=2021-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342787, encodeId=42511342e873a, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Sat Feb 27 00:44:46 CST 2021, time=2021-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1414454, encodeId=429814144540b, content=<a href='/topic/show?id=8e95364321f' target=_blank style='color:#2F92EE;'>#南非#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36432, encryptionId=8e95364321f, topicName=南非)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=83403055912, createdName=hongbochen, createdTime=Sat Feb 27 00:44:46 CST 2021, time=2021-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562058, encodeId=d36f15620589b, content=<a href='/topic/show?id=6875513376' target=_blank style='color:#2F92EE;'>#COVID-19候选疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5133, encryptionId=6875513376, topicName=COVID-19候选疫苗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=077d15252580, createdName=piaojinhua, createdTime=Sat Feb 27 00:44:46 CST 2021, time=2021-02-27, status=1, ipAttribution=)]
    2022-01-03 12498f17m66暂无昵称

    #候选疫苗#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1937313, encodeId=036e193e313e5, content=<a href='/topic/show?id=d6262e4688b' target=_blank style='color:#2F92EE;'>#候选疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27468, encryptionId=d6262e4688b, topicName=候选疫苗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e5742500212, createdName=12498f17m66暂无昵称, createdTime=Mon Jan 03 08:44:46 CST 2022, time=2022-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2008782, encodeId=81742008e82e2, content=<a href='/topic/show?id=db6969548d' target=_blank style='color:#2F92EE;'>#eRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6954, encryptionId=db6969548d, topicName=eRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Mon Jan 10 03:44:46 CST 2022, time=2022-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2025281, encodeId=611b20252812b, content=<a href='/topic/show?id=6b8a230e815' target=_blank style='color:#2F92EE;'>#临床阶段#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23078, encryptionId=6b8a230e815, topicName=临床阶段)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d39f177, createdName=lixiao3326, createdTime=Fri Jan 14 04:44:46 CST 2022, time=2022-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=952867, encodeId=462995286e9b, content=赚积分, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=82d12201325, createdName=黑布林, createdTime=Wed Mar 31 18:41:37 CST 2021, time=2021-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899462, encodeId=345b1899462b3, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Wed Aug 04 23:44:46 CST 2021, time=2021-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=947905, encodeId=ec0294e9053a, content=！, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqicXS4Klkk29P7uiaLsaE4sM2BIzwEbpMXmDq9icj7Pia2Piaf90l5zdma3uAsLBz3YOLXiaSPNh5VJWpw/132, createdBy=e1aa2416324, createdName=真真日上, createdTime=Sat Mar 13 17:55:21 CST 2021, time=2021-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=944616, encodeId=36e594461645, content=期待结果, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e83131645, createdName=caicunliang, createdTime=Tue Mar 02 00:07:51 CST 2021, time=2021-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342787, encodeId=42511342e873a, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Sat Feb 27 00:44:46 CST 2021, time=2021-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1414454, encodeId=429814144540b, content=<a href='/topic/show?id=8e95364321f' target=_blank style='color:#2F92EE;'>#南非#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36432, encryptionId=8e95364321f, topicName=南非)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=83403055912, createdName=hongbochen, createdTime=Sat Feb 27 00:44:46 CST 2021, time=2021-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562058, encodeId=d36f15620589b, content=<a href='/topic/show?id=6875513376' target=_blank style='color:#2F92EE;'>#COVID-19候选疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5133, encryptionId=6875513376, topicName=COVID-19候选疫苗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=077d15252580, createdName=piaojinhua, createdTime=Sat Feb 27 00:44:46 CST 2021, time=2021-02-27, status=1, ipAttribution=)]
    2022-01-10 般若傻瓜

    #eRNA#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1937313, encodeId=036e193e313e5, content=<a href='/topic/show?id=d6262e4688b' target=_blank style='color:#2F92EE;'>#候选疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27468, encryptionId=d6262e4688b, topicName=候选疫苗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e5742500212, createdName=12498f17m66暂无昵称, createdTime=Mon Jan 03 08:44:46 CST 2022, time=2022-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2008782, encodeId=81742008e82e2, content=<a href='/topic/show?id=db6969548d' target=_blank style='color:#2F92EE;'>#eRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6954, encryptionId=db6969548d, topicName=eRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Mon Jan 10 03:44:46 CST 2022, time=2022-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2025281, encodeId=611b20252812b, content=<a href='/topic/show?id=6b8a230e815' target=_blank style='color:#2F92EE;'>#临床阶段#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23078, encryptionId=6b8a230e815, topicName=临床阶段)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d39f177, createdName=lixiao3326, createdTime=Fri Jan 14 04:44:46 CST 2022, time=2022-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=952867, encodeId=462995286e9b, content=赚积分, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=82d12201325, createdName=黑布林, createdTime=Wed Mar 31 18:41:37 CST 2021, time=2021-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899462, encodeId=345b1899462b3, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Wed Aug 04 23:44:46 CST 2021, time=2021-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=947905, encodeId=ec0294e9053a, content=！, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqicXS4Klkk29P7uiaLsaE4sM2BIzwEbpMXmDq9icj7Pia2Piaf90l5zdma3uAsLBz3YOLXiaSPNh5VJWpw/132, createdBy=e1aa2416324, createdName=真真日上, createdTime=Sat Mar 13 17:55:21 CST 2021, time=2021-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=944616, encodeId=36e594461645, content=期待结果, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e83131645, createdName=caicunliang, createdTime=Tue Mar 02 00:07:51 CST 2021, time=2021-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342787, encodeId=42511342e873a, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Sat Feb 27 00:44:46 CST 2021, time=2021-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1414454, encodeId=429814144540b, content=<a href='/topic/show?id=8e95364321f' target=_blank style='color:#2F92EE;'>#南非#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36432, encryptionId=8e95364321f, topicName=南非)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=83403055912, createdName=hongbochen, createdTime=Sat Feb 27 00:44:46 CST 2021, time=2021-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562058, encodeId=d36f15620589b, content=<a href='/topic/show?id=6875513376' target=_blank style='color:#2F92EE;'>#COVID-19候选疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5133, encryptionId=6875513376, topicName=COVID-19候选疫苗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=077d15252580, createdName=piaojinhua, createdTime=Sat Feb 27 00:44:46 CST 2021, time=2021-02-27, status=1, ipAttribution=)]
    2022-01-14 lixiao3326

    #临床阶段#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1937313, encodeId=036e193e313e5, content=<a href='/topic/show?id=d6262e4688b' target=_blank style='color:#2F92EE;'>#候选疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27468, encryptionId=d6262e4688b, topicName=候选疫苗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e5742500212, createdName=12498f17m66暂无昵称, createdTime=Mon Jan 03 08:44:46 CST 2022, time=2022-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2008782, encodeId=81742008e82e2, content=<a href='/topic/show?id=db6969548d' target=_blank style='color:#2F92EE;'>#eRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6954, encryptionId=db6969548d, topicName=eRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Mon Jan 10 03:44:46 CST 2022, time=2022-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2025281, encodeId=611b20252812b, content=<a href='/topic/show?id=6b8a230e815' target=_blank style='color:#2F92EE;'>#临床阶段#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23078, encryptionId=6b8a230e815, topicName=临床阶段)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d39f177, createdName=lixiao3326, createdTime=Fri Jan 14 04:44:46 CST 2022, time=2022-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=952867, encodeId=462995286e9b, content=赚积分, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=82d12201325, createdName=黑布林, createdTime=Wed Mar 31 18:41:37 CST 2021, time=2021-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899462, encodeId=345b1899462b3, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Wed Aug 04 23:44:46 CST 2021, time=2021-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=947905, encodeId=ec0294e9053a, content=！, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqicXS4Klkk29P7uiaLsaE4sM2BIzwEbpMXmDq9icj7Pia2Piaf90l5zdma3uAsLBz3YOLXiaSPNh5VJWpw/132, createdBy=e1aa2416324, createdName=真真日上, createdTime=Sat Mar 13 17:55:21 CST 2021, time=2021-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=944616, encodeId=36e594461645, content=期待结果, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e83131645, createdName=caicunliang, createdTime=Tue Mar 02 00:07:51 CST 2021, time=2021-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342787, encodeId=42511342e873a, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Sat Feb 27 00:44:46 CST 2021, time=2021-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1414454, encodeId=429814144540b, content=<a href='/topic/show?id=8e95364321f' target=_blank style='color:#2F92EE;'>#南非#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36432, encryptionId=8e95364321f, topicName=南非)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=83403055912, createdName=hongbochen, createdTime=Sat Feb 27 00:44:46 CST 2021, time=2021-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562058, encodeId=d36f15620589b, content=<a href='/topic/show?id=6875513376' target=_blank style='color:#2F92EE;'>#COVID-19候选疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5133, encryptionId=6875513376, topicName=COVID-19候选疫苗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=077d15252580, createdName=piaojinhua, createdTime=Sat Feb 27 00:44:46 CST 2021, time=2021-02-27, status=1, ipAttribution=)]
    2021-03-31 黑布林

    赚积分

    1

    展开1条回复
  5. [GetPortalCommentsPageByObjectIdResponse(id=1937313, encodeId=036e193e313e5, content=<a href='/topic/show?id=d6262e4688b' target=_blank style='color:#2F92EE;'>#候选疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27468, encryptionId=d6262e4688b, topicName=候选疫苗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e5742500212, createdName=12498f17m66暂无昵称, createdTime=Mon Jan 03 08:44:46 CST 2022, time=2022-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2008782, encodeId=81742008e82e2, content=<a href='/topic/show?id=db6969548d' target=_blank style='color:#2F92EE;'>#eRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6954, encryptionId=db6969548d, topicName=eRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Mon Jan 10 03:44:46 CST 2022, time=2022-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2025281, encodeId=611b20252812b, content=<a href='/topic/show?id=6b8a230e815' target=_blank style='color:#2F92EE;'>#临床阶段#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23078, encryptionId=6b8a230e815, topicName=临床阶段)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d39f177, createdName=lixiao3326, createdTime=Fri Jan 14 04:44:46 CST 2022, time=2022-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=952867, encodeId=462995286e9b, content=赚积分, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=82d12201325, createdName=黑布林, createdTime=Wed Mar 31 18:41:37 CST 2021, time=2021-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899462, encodeId=345b1899462b3, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Wed Aug 04 23:44:46 CST 2021, time=2021-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=947905, encodeId=ec0294e9053a, content=！, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqicXS4Klkk29P7uiaLsaE4sM2BIzwEbpMXmDq9icj7Pia2Piaf90l5zdma3uAsLBz3YOLXiaSPNh5VJWpw/132, createdBy=e1aa2416324, createdName=真真日上, createdTime=Sat Mar 13 17:55:21 CST 2021, time=2021-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=944616, encodeId=36e594461645, content=期待结果, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e83131645, createdName=caicunliang, createdTime=Tue Mar 02 00:07:51 CST 2021, time=2021-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342787, encodeId=42511342e873a, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Sat Feb 27 00:44:46 CST 2021, time=2021-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1414454, encodeId=429814144540b, content=<a href='/topic/show?id=8e95364321f' target=_blank style='color:#2F92EE;'>#南非#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36432, encryptionId=8e95364321f, topicName=南非)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=83403055912, createdName=hongbochen, createdTime=Sat Feb 27 00:44:46 CST 2021, time=2021-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562058, encodeId=d36f15620589b, content=<a href='/topic/show?id=6875513376' target=_blank style='color:#2F92EE;'>#COVID-19候选疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5133, encryptionId=6875513376, topicName=COVID-19候选疫苗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=077d15252580, createdName=piaojinhua, createdTime=Sat Feb 27 00:44:46 CST 2021, time=2021-02-27, status=1, ipAttribution=)]
    2021-08-04 jinweidong

    #特异性#

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1937313, encodeId=036e193e313e5, content=<a href='/topic/show?id=d6262e4688b' target=_blank style='color:#2F92EE;'>#候选疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27468, encryptionId=d6262e4688b, topicName=候选疫苗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e5742500212, createdName=12498f17m66暂无昵称, createdTime=Mon Jan 03 08:44:46 CST 2022, time=2022-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2008782, encodeId=81742008e82e2, content=<a href='/topic/show?id=db6969548d' target=_blank style='color:#2F92EE;'>#eRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6954, encryptionId=db6969548d, topicName=eRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Mon Jan 10 03:44:46 CST 2022, time=2022-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2025281, encodeId=611b20252812b, content=<a href='/topic/show?id=6b8a230e815' target=_blank style='color:#2F92EE;'>#临床阶段#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23078, encryptionId=6b8a230e815, topicName=临床阶段)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d39f177, createdName=lixiao3326, createdTime=Fri Jan 14 04:44:46 CST 2022, time=2022-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=952867, encodeId=462995286e9b, content=赚积分, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=82d12201325, createdName=黑布林, createdTime=Wed Mar 31 18:41:37 CST 2021, time=2021-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899462, encodeId=345b1899462b3, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Wed Aug 04 23:44:46 CST 2021, time=2021-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=947905, encodeId=ec0294e9053a, content=！, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqicXS4Klkk29P7uiaLsaE4sM2BIzwEbpMXmDq9icj7Pia2Piaf90l5zdma3uAsLBz3YOLXiaSPNh5VJWpw/132, createdBy=e1aa2416324, createdName=真真日上, createdTime=Sat Mar 13 17:55:21 CST 2021, time=2021-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=944616, encodeId=36e594461645, content=期待结果, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e83131645, createdName=caicunliang, createdTime=Tue Mar 02 00:07:51 CST 2021, time=2021-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342787, encodeId=42511342e873a, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Sat Feb 27 00:44:46 CST 2021, time=2021-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1414454, encodeId=429814144540b, content=<a href='/topic/show?id=8e95364321f' target=_blank style='color:#2F92EE;'>#南非#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36432, encryptionId=8e95364321f, topicName=南非)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=83403055912, createdName=hongbochen, createdTime=Sat Feb 27 00:44:46 CST 2021, time=2021-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562058, encodeId=d36f15620589b, content=<a href='/topic/show?id=6875513376' target=_blank style='color:#2F92EE;'>#COVID-19候选疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5133, encryptionId=6875513376, topicName=COVID-19候选疫苗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=077d15252580, createdName=piaojinhua, createdTime=Sat Feb 27 00:44:46 CST 2021, time=2021-02-27, status=1, ipAttribution=)]
    2021-03-13 真真日上

    ！

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1937313, encodeId=036e193e313e5, content=<a href='/topic/show?id=d6262e4688b' target=_blank style='color:#2F92EE;'>#候选疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27468, encryptionId=d6262e4688b, topicName=候选疫苗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e5742500212, createdName=12498f17m66暂无昵称, createdTime=Mon Jan 03 08:44:46 CST 2022, time=2022-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2008782, encodeId=81742008e82e2, content=<a href='/topic/show?id=db6969548d' target=_blank style='color:#2F92EE;'>#eRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6954, encryptionId=db6969548d, topicName=eRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Mon Jan 10 03:44:46 CST 2022, time=2022-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2025281, encodeId=611b20252812b, content=<a href='/topic/show?id=6b8a230e815' target=_blank style='color:#2F92EE;'>#临床阶段#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23078, encryptionId=6b8a230e815, topicName=临床阶段)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d39f177, createdName=lixiao3326, createdTime=Fri Jan 14 04:44:46 CST 2022, time=2022-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=952867, encodeId=462995286e9b, content=赚积分, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=82d12201325, createdName=黑布林, createdTime=Wed Mar 31 18:41:37 CST 2021, time=2021-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899462, encodeId=345b1899462b3, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Wed Aug 04 23:44:46 CST 2021, time=2021-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=947905, encodeId=ec0294e9053a, content=！, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqicXS4Klkk29P7uiaLsaE4sM2BIzwEbpMXmDq9icj7Pia2Piaf90l5zdma3uAsLBz3YOLXiaSPNh5VJWpw/132, createdBy=e1aa2416324, createdName=真真日上, createdTime=Sat Mar 13 17:55:21 CST 2021, time=2021-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=944616, encodeId=36e594461645, content=期待结果, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e83131645, createdName=caicunliang, createdTime=Tue Mar 02 00:07:51 CST 2021, time=2021-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342787, encodeId=42511342e873a, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Sat Feb 27 00:44:46 CST 2021, time=2021-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1414454, encodeId=429814144540b, content=<a href='/topic/show?id=8e95364321f' target=_blank style='color:#2F92EE;'>#南非#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36432, encryptionId=8e95364321f, topicName=南非)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=83403055912, createdName=hongbochen, createdTime=Sat Feb 27 00:44:46 CST 2021, time=2021-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562058, encodeId=d36f15620589b, content=<a href='/topic/show?id=6875513376' target=_blank style='color:#2F92EE;'>#COVID-19候选疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5133, encryptionId=6875513376, topicName=COVID-19候选疫苗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=077d15252580, createdName=piaojinhua, createdTime=Sat Feb 27 00:44:46 CST 2021, time=2021-02-27, status=1, ipAttribution=)]
    2021-03-02 caicunliang

    期待结果

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1937313, encodeId=036e193e313e5, content=<a href='/topic/show?id=d6262e4688b' target=_blank style='color:#2F92EE;'>#候选疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27468, encryptionId=d6262e4688b, topicName=候选疫苗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e5742500212, createdName=12498f17m66暂无昵称, createdTime=Mon Jan 03 08:44:46 CST 2022, time=2022-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2008782, encodeId=81742008e82e2, content=<a href='/topic/show?id=db6969548d' target=_blank style='color:#2F92EE;'>#eRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6954, encryptionId=db6969548d, topicName=eRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Mon Jan 10 03:44:46 CST 2022, time=2022-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2025281, encodeId=611b20252812b, content=<a href='/topic/show?id=6b8a230e815' target=_blank style='color:#2F92EE;'>#临床阶段#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23078, encryptionId=6b8a230e815, topicName=临床阶段)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d39f177, createdName=lixiao3326, createdTime=Fri Jan 14 04:44:46 CST 2022, time=2022-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=952867, encodeId=462995286e9b, content=赚积分, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=82d12201325, createdName=黑布林, createdTime=Wed Mar 31 18:41:37 CST 2021, time=2021-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899462, encodeId=345b1899462b3, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Wed Aug 04 23:44:46 CST 2021, time=2021-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=947905, encodeId=ec0294e9053a, content=！, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqicXS4Klkk29P7uiaLsaE4sM2BIzwEbpMXmDq9icj7Pia2Piaf90l5zdma3uAsLBz3YOLXiaSPNh5VJWpw/132, createdBy=e1aa2416324, createdName=真真日上, createdTime=Sat Mar 13 17:55:21 CST 2021, time=2021-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=944616, encodeId=36e594461645, content=期待结果, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e83131645, createdName=caicunliang, createdTime=Tue Mar 02 00:07:51 CST 2021, time=2021-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342787, encodeId=42511342e873a, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Sat Feb 27 00:44:46 CST 2021, time=2021-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1414454, encodeId=429814144540b, content=<a href='/topic/show?id=8e95364321f' target=_blank style='color:#2F92EE;'>#南非#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36432, encryptionId=8e95364321f, topicName=南非)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=83403055912, createdName=hongbochen, createdTime=Sat Feb 27 00:44:46 CST 2021, time=2021-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562058, encodeId=d36f15620589b, content=<a href='/topic/show?id=6875513376' target=_blank style='color:#2F92EE;'>#COVID-19候选疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5133, encryptionId=6875513376, topicName=COVID-19候选疫苗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=077d15252580, createdName=piaojinhua, createdTime=Sat Feb 27 00:44:46 CST 2021, time=2021-02-27, status=1, ipAttribution=)]
    2021-02-27 12498dabm77暂无昵称

    #变异#

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1937313, encodeId=036e193e313e5, content=<a href='/topic/show?id=d6262e4688b' target=_blank style='color:#2F92EE;'>#候选疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27468, encryptionId=d6262e4688b, topicName=候选疫苗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e5742500212, createdName=12498f17m66暂无昵称, createdTime=Mon Jan 03 08:44:46 CST 2022, time=2022-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2008782, encodeId=81742008e82e2, content=<a href='/topic/show?id=db6969548d' target=_blank style='color:#2F92EE;'>#eRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6954, encryptionId=db6969548d, topicName=eRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Mon Jan 10 03:44:46 CST 2022, time=2022-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2025281, encodeId=611b20252812b, content=<a href='/topic/show?id=6b8a230e815' target=_blank style='color:#2F92EE;'>#临床阶段#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23078, encryptionId=6b8a230e815, topicName=临床阶段)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d39f177, createdName=lixiao3326, createdTime=Fri Jan 14 04:44:46 CST 2022, time=2022-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=952867, encodeId=462995286e9b, content=赚积分, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=82d12201325, createdName=黑布林, createdTime=Wed Mar 31 18:41:37 CST 2021, time=2021-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899462, encodeId=345b1899462b3, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Wed Aug 04 23:44:46 CST 2021, time=2021-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=947905, encodeId=ec0294e9053a, content=！, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqicXS4Klkk29P7uiaLsaE4sM2BIzwEbpMXmDq9icj7Pia2Piaf90l5zdma3uAsLBz3YOLXiaSPNh5VJWpw/132, createdBy=e1aa2416324, createdName=真真日上, createdTime=Sat Mar 13 17:55:21 CST 2021, time=2021-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=944616, encodeId=36e594461645, content=期待结果, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e83131645, createdName=caicunliang, createdTime=Tue Mar 02 00:07:51 CST 2021, time=2021-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342787, encodeId=42511342e873a, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Sat Feb 27 00:44:46 CST 2021, time=2021-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1414454, encodeId=429814144540b, content=<a href='/topic/show?id=8e95364321f' target=_blank style='color:#2F92EE;'>#南非#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36432, encryptionId=8e95364321f, topicName=南非)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=83403055912, createdName=hongbochen, createdTime=Sat Feb 27 00:44:46 CST 2021, time=2021-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562058, encodeId=d36f15620589b, content=<a href='/topic/show?id=6875513376' target=_blank style='color:#2F92EE;'>#COVID-19候选疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5133, encryptionId=6875513376, topicName=COVID-19候选疫苗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=077d15252580, createdName=piaojinhua, createdTime=Sat Feb 27 00:44:46 CST 2021, time=2021-02-27, status=1, ipAttribution=)]
    2021-02-27 hongbochen

    #南非#

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=1937313, encodeId=036e193e313e5, content=<a href='/topic/show?id=d6262e4688b' target=_blank style='color:#2F92EE;'>#候选疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27468, encryptionId=d6262e4688b, topicName=候选疫苗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e5742500212, createdName=12498f17m66暂无昵称, createdTime=Mon Jan 03 08:44:46 CST 2022, time=2022-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2008782, encodeId=81742008e82e2, content=<a href='/topic/show?id=db6969548d' target=_blank style='color:#2F92EE;'>#eRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6954, encryptionId=db6969548d, topicName=eRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Mon Jan 10 03:44:46 CST 2022, time=2022-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2025281, encodeId=611b20252812b, content=<a href='/topic/show?id=6b8a230e815' target=_blank style='color:#2F92EE;'>#临床阶段#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23078, encryptionId=6b8a230e815, topicName=临床阶段)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d39f177, createdName=lixiao3326, createdTime=Fri Jan 14 04:44:46 CST 2022, time=2022-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=952867, encodeId=462995286e9b, content=赚积分, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=82d12201325, createdName=黑布林, createdTime=Wed Mar 31 18:41:37 CST 2021, time=2021-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899462, encodeId=345b1899462b3, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Wed Aug 04 23:44:46 CST 2021, time=2021-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=947905, encodeId=ec0294e9053a, content=！, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqicXS4Klkk29P7uiaLsaE4sM2BIzwEbpMXmDq9icj7Pia2Piaf90l5zdma3uAsLBz3YOLXiaSPNh5VJWpw/132, createdBy=e1aa2416324, createdName=真真日上, createdTime=Sat Mar 13 17:55:21 CST 2021, time=2021-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=944616, encodeId=36e594461645, content=期待结果, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e83131645, createdName=caicunliang, createdTime=Tue Mar 02 00:07:51 CST 2021, time=2021-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342787, encodeId=42511342e873a, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Sat Feb 27 00:44:46 CST 2021, time=2021-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1414454, encodeId=429814144540b, content=<a href='/topic/show?id=8e95364321f' target=_blank style='color:#2F92EE;'>#南非#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36432, encryptionId=8e95364321f, topicName=南非)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=83403055912, createdName=hongbochen, createdTime=Sat Feb 27 00:44:46 CST 2021, time=2021-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562058, encodeId=d36f15620589b, content=<a href='/topic/show?id=6875513376' target=_blank style='color:#2F92EE;'>#COVID-19候选疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5133, encryptionId=6875513376, topicName=COVID-19候选疫苗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=077d15252580, createdName=piaojinhua, createdTime=Sat Feb 27 00:44:46 CST 2021, time=2021-02-27, status=1, ipAttribution=)]
    2021-02-27 piaojinhua

    #COVID-19候选疫苗#

    0

以上为热门评论，梅斯医学App还有更多内容

相关资讯

Moderna确认与日本就实验性疫苗COVID-19疫苗供应进行会谈

Moderna近日表示，正在与日本政府商讨一项潜在的预先购买协议，日本政府将购买4000万或更多剂量的实验性COVID-19疫苗（mRNA-1273）。

Moderna宣布其新冠疫苗mRNA-1273有效率达94.5％

Moderna指出，在第一次中期分析中发现了11例严重COVID-19病例，而这些病例均发生在安慰剂组。

又一大利好消息！Moderna新冠疫苗三期临床试验有效性高达94.5%

mRNA-1273三期临床试验初步数据有效性达94.5%

英国MHRA开始对Moderna新冠病毒疫苗进行滚动审查

mRNA-1273第一阶段研究中期分析结果显示，接受两剂疫苗的参与者对SARS-CoV-2具有快速且强烈的免疫反应。

Moderna宣布欧盟委员会批准COVID-19疫苗（mRNA-1273）的首批8000万剂的预购协议

生物技术公司Moderna今天宣布，欧盟委员会已批准一项协议，以确保获得8000万剂mRNA-1273（针对COVID-19的疫苗候选药物）。

Moderna宣布与英国政府修订当前的COVID-19疫苗（mRNA-1273）供应协议

生物技术公司Moderna今天宣布与英国政府达成供应协议，将另外提供200万剂COVID-19候选疫苗（mRNA-1273），将于2021年3月开始运抵英国。

拓展阅读

Moderna新冠疫苗对青少年保护力达100％，有望在6月初获FDA批准

Moderna周二表示，其研发的mRNA新冠疫苗在一项针对12至17岁青少年的研究中显示出具有100％保护效果，是继辉瑞mRNA新冠疫苗之后第二种显示出对青少年人群中具有高疗效的疫苗。

Moderna疫苗有效性降至90%

两次注射Moderna COVID-19疫苗的时间间隔为28天，在特殊情况下可以延长至42天。

美国NIH启动研究接种疫苗后还要不要戴口罩？

科学家们仍然不知道免疫接种的人是否会获得无症状感染或充当将病毒传播给他人的携带者。随着越来越多的美国人接种疫苗，NIH这项研究旨在回答这些问题。

重磅! 使用过破尿酸美容人群或许不合适接种Moderna疫苗，恐引发严重过敏反应

波士顿医疗中心(Boston Medical Center)的肿瘤学家萨德尔扎德(Hossein Sadrzadeh) 于24日进行了Moderna疫苗的接种，他曾有严重的贝类过敏。 他几乎在接种疫苗

Moderna新冠疫苗的存储、运输和接种温度具有明显优势

Moderna宣布其COVID-19候选疫苗在2至8度（标准家用或医用冰箱温度）可保持稳定30天，在-20度可保持稳定六个月，在室温下则可保存12小时。